Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT00950456
Other study ID # 820901
Secondary ID
Status Completed
Phase N/A
First received July 30, 2009
Last updated October 7, 2015
Start date November 2009
Est. completion date February 2011

Study information

Verified date May 2011
Source Nanotherapeutics, Inc.
Contact n/a
Is FDA regulated No
Health authority Austria: Agency for Health and Food Safety
Study type Observational

Clinical Trial Summary

The purpose of this observational study, which will be initiated as soon as the licensed H1N1 Pandemic Influenza Vaccine is used in a mass vaccination campaign, is to estimate the incidence of any medically-attended adverse events in all vaccinated subjects.


Recruitment information / eligibility

Status Completed
Enrollment 3216
Est. completion date February 2011
Est. primary completion date December 2010
Accepts healthy volunteers Accepts Healthy Volunteers
Gender Both
Age group 2 Months and older
Eligibility Inclusion Criteria:

Male and female subjects, per indication on license or per official vaccine recommendations, will be eligible for participation in this study if:

- They will be administered CELVAPAN (= Baxter´s H1N1 pandemic influenza vaccine)

- They are 2 months of age or older at the time of first vaccine administration

- Their medical history is available

- The investigator believes they will comply with the foreseen vaccination schedule and will reliably observe signs or symptoms of adverse events during the observational period

- They and/or their parent(s)/legal guardian(s) provide written informed consent, and assent where appropriate, prior to study entry according to national law

Exclusion Criteria:

Male and female subjects will be excluded from participation in this study if:

- They have already been administered another H1N1 pandemic vaccine

- They have any contraindication to vaccination (as per the Summary of Product Characteristics and/or relevant national immunization guidelines)

Study Design

Observational Model: Ecologic or Community, Time Perspective: Prospective


Related Conditions & MeSH terms


Intervention

Biological:
H1N1 Pandemic Influenza Vaccine (whole virion, Vero Cell-derived, inactivated)
It is anticipated that subjects will receive two intramuscular injections approximately 3 weeks apart. The vaccine will be provided in two doses, one for adults, the other for children.

Locations

Country Name City State
Austria General Practice Bludenz
Austria General Practice Fulpmes
Austria General Practice Hall in Tirol
Austria General Practice Innsbruck
Austria Practice for Travel Medicine Innsbruck
Austria City Council (Magistrat) Klagenfurt (Health & Food Department) Klagenfurt
Austria General Practice Kufstein
Austria General Practice Mariapfarr
Austria General Practice Oberperfuss
Austria General Practice Salzburg
Austria General Practice Telfs
Austria Hanusch Hospital Vienna
Austria Medical University of Vienna, Department of Internal Medicine I, Division of Infectious Diseases and Tropical Medicine Vienna
Austria Medical University of Vienna, Department of Specific Prophylaxis and Tropical Medicine Vienna
Austria Wiener Gebietskrankenkasse (Health insurance center Vienna) Vienna
Austria General Practice Voitsberg
Austria General Practice Wels

Sponsors (1)

Lead Sponsor Collaborator
Nanotherapeutics, Inc.

Country where clinical trial is conducted

Austria, 

See also
  Status Clinical Trial Phase
Completed NCT05523089 - The Effectiveness of CD388 to Prevent Flu in an Influenza Challenge Model in Healthy Adults Phase 2
Completed NCT05009251 - Using Explainable AI Risk Predictions to Nudge Influenza Vaccine Uptake N/A
Completed NCT03282240 - Safety and Immunogenicity of High-Dose Quadrivalent Influenza Vaccine in Participants ≥65 Years in the US Phase 3
Completed NCT00971425 - Evaluation of the Immune Response and the Safety of a Pandemic Influenza Candidate Vaccine (H1N1) Phase 3
Completed NCT00968539 - Study to Evaluate the Immunogenicity & Safety of an Investigational Influenza Vaccine (H1N1) in Adults Phase 3
Completed NCT00968526 - Study to Evaluate Immunogenicity and Safety of an Investigational Influenza Vaccine (H1N1) in Adults Phase 3
Completed NCT05525494 - Patient Portal Flu Vaccine Reminders (5) N/A
Completed NCT04074928 - Safety and Immunogenicity Study of QIVc in Healthy Pediatric Subjects Phase 3
Completed NCT04695717 - This Study Was Conducted to Evaluate the Safety and Immunogenicity of IVACFLU-S Produced in Children From 6 Months to Under 18 Years Old and the Elderly Over 60 Years Old in Vietnam Phase 3
Completed NCT05012163 - Lottery Incentive Nudges to Increase Influenza Vaccinations N/A
Completed NCT03888989 - Response to Influenza Vaccine During Pregnancy Phase 1
Completed NCT04109222 - Collection of Serum Samples From Children and Older Adults Receiving the 2019-2020 Formulations of Fluzone® Quadrivalent and Fluzone® High-Dose Influenza Vaccines, Respectively Phase 4
Completed NCT02587221 - Clinical Study to Evaluate the Efficacy, Safety and Immunogenicity of an MF59-Adjuvanted Quadrivalent Influenza Vaccine Compared to Non-influenza Vaccine Comparator in Adults ≥ 65 Years of Age Phase 3
Completed NCT03453801 - The Role of CD4+ Memory Phenotype, Memory, and Effector T Cells in Vaccination and Infection Phase 1
Completed NCT01440387 - A Study of Immunogenicity and Safety of GSK Biologicals' Influenza Vaccine FLU-Q-QIV in Adults Aged 18 Years and Older Phase 3
Terminated NCT01195779 - Trial to Evaluate Safety and Immunogenicity of GSK Biologicals' Influenza Vaccine GSK2584786A in Healthy Children Phase 2
Completed NCT03321968 - Lot-to-lot Consistency of a Plant-Derived Quadrivalent Virus-Like Particles Influenza Vaccine in Healthy Adults Phase 3
Completed NCT00972517 - Study to Evaluate the Immunogenicity and Safety of an Investigational Influenza Vaccine (H1N1) in Children Phase 3
Completed NCT04570904 - Broadening Our Understanding of Early Versus Late Influenza Vaccine Effectiveness
Recruiting NCT03331991 - Prevention of Influenza and Other Wintertime Respiratory Viruses Among Healthcare Professionals in Israel N/A